Zurcher Kantonalbank Zurich Cantonalbank Has $37.59 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 6.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 507,769 shares of the medical research company’s stock after buying an additional 29,351 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Edwards Lifesciences were worth $37,590,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of EW. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Trading Down 2.6 %

Shares of EW stock opened at $68.49 on Tuesday. The stock’s fifty day moving average price is $72.14 and its two-hundred day moving average price is $70.37. The company has a market cap of $40.26 billion, a PE ratio of 9.83, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,303 shares of company stock valued at $3,255,356 in the last 90 days. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.